Systematic adjudication of myocardial infarction end-points in an international clinical trial

[1] Antman EM(1996)A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 335 775-782

[2] Temple R(1994)Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330 956-961

[3] Pledger GW(1997)Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336 1689-1696

[4] Epstein AE(1994)Collaborative overview of randomised trials of antiplatelet therapy I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308 81-106

[5] Carlson MD(1996)Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 94 911-922

[6] Fogoros RN(1998)Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation: a randomized, placebo-controlled, clinical trial. N Engl J Med 339 436-443

[7] Higgins SL(1998)A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 338 1498-1505

[8] Venditti FJ(1998)Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 338 1488-1497

[9] Remington RD(1997)Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention. Lancet 349 1422-1428

[10] Moussa MA(1998)Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 352 87-92

[1] Antman EM(1996)A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 335 775-782

[2] Temple R(1994)Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330 956-961

[3] Pledger GW(1997)Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336 1689-1696

[4] Epstein AE(1994)Collaborative overview of randomised trials of antiplatelet therapy I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308 81-106

[5] Carlson MD(1996)Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 94 911-922

[6] Fogoros RN(1998)Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation: a randomized, placebo-controlled, clinical trial. N Engl J Med 339 436-443

[7] Higgins SL(1998)A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 338 1498-1505

[8] Venditti FJ(1998)Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 338 1488-1497

[9] Remington RD(1997)Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention. Lancet 349 1422-1428

[10] Moussa MA(1998)Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 352 87-92